Tislelizumab (TIS) Plus Chemotherapy (CT) Vs Placebo (PBO) Plus CT in HER2-negative Advanced or Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma (GC/GEJC): PDL1 Biomarker Analysis from RATIONALE-305
ANNALS OF ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined